Connect with us

Hi, what are you looking for?

Friday, Sep 22, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

AI and Autonomy

Cannabis and psychedelics law firm aims to help marginalized communities with AI

The firm has allocated US$100K for time and resources involved in finding ways to utilize AI technologies for its specific needs

Mr. Cannabis Law firm invests US$100K in AI to streamline its activity
Photo by Yash Lucid via Pexels

A small Florida law firm is investing in artificial intelligence and plans to make medical cannabis applications more financially feasible for marginalized communities and low-income applicants through its use.

Mr. Cannabis Law announced its US$100,000 investment in AI on Monday for automating medical cannabis license applications and cannabis real estate deals among other things. The firm has allocated that amount for the time and resources involved with testing various AI technologies and their different functions to determine which ones suit its specific needs.

“We’re taking some of the current AI that’s out there and trying to build our own datasets so that we can have a specialized AI and machine learning platform applicable to cannabis and psychedelics,” said the firm’s Founding Partner Dustin Robinson in an interview with Mugglehead.

Dustin Robinson. Photo via Mr. Cannabis Law

According to Mr. Cannabis Law, the average cost of a medical cannabis license application in competitive states like Florida is somewhere around US$350,000. The firm has a goal to use AI to get that number down tenfold to around US$35,000 so that applications are more financially feasible for those with limited resources.

Mr. Cannabis Law will be carefully reviewing and editing any work completed by AI, which will ideally become a less time-consuming process as the technology evolves. “I think it’s really, really important for law firms right now to do significant review of AI since it’s such an early technology,” said Robinson.

Read more: Scaling AI is the top priority for 78% of information executives: MIT Technology Review Insights

Read more: RISE Dispensaries initiates ‘Thanks, Dick’ campaign to facetiously celebrate Richard Nixon

Currently, the firm is focused on developing its own AI and machine learning platform to suit its needs, but Robinson says once that has been accomplished other firms may be able to utilize it.

“I do have a long-term vision that if we’re able to build a unique platform that would be useful to other law firms it could potentially grow into something that we would offer them to streamline their activity,” said Robinson.

Mr. Cannabis Law has two offices and five attorneys and is currently practicing in Florida, Connecticut, New York and New Jersey. Robinson recently spoke about psychedelics at the Psychedelic Series Panel in Nashville, Tennessee and discussed investing in the industry at Miami’s Benzinga Psychedelics Capital Conference in April.

“Ultimately, I believe law firms that don’t embrace AI will be left behind,” he added.

Other cannabis and psychedelics law firms in the U.S. include Husch Blackwell LLP, the Plant Medicine Law Group and Phillips Lytle LLP, which opened its Psychedelic & Mental Health Therapies Practice in New York last summer.

The news comes as many start-up companies involved with AI technologies have been receiving vast sums of money from investors, such as Spellbook (formerly Rally), which recently secured an investment of US$10.9 million from Moxxie Ventures, Thomson Reuters Ventures and others to develop AI technology that enables lawyers to draft and review legal contracts at a far greater speed.

 

Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

rowan@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AI and Autonomy

This is the largest acquisition the technology company has ever made and the sector's largest transaction this year

AI and Autonomy

The tech corporation is aiming to train 2 million people in its use by the end of 2026

AI and Autonomy

The program is meant to support healthcare professionals and speed up decisions regarding follow-ups or referrals

AI and Autonomy

The expanded partnership offers a scalable, cost-effective platform using NVIDIA technology to augment Infosys' Responsible AI Toolkit